-
Product Insights
![]()
AcelRx Pharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023
AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo in Europe), is a single sufentanil sublingual tablet for treating of moderate-to-severe acute pain. Its pipeline also includes Zalviso (for US market), a drug and device combination product for the management of moderate to severe acute pain in adults. AcelRx developed a proprietary, non-invasive, sublingual formulation technology to deliver its highly lipophilic...
-
Product Insights
![]()
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
IRAK-4 Pipeline Products Market Report Overview Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. The ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation. The IRAK-4 pipeline...
-
Product Insights
![]()
Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) targeted pipeline therapeutics. The report provides comprehensive information...
-
Product Insights
![]()
Geranylgeranyl Pyrophosphate Synthase (Geranylgeranyl Diphosphate Synthase or Dimethylallyltranstransferase or Farnesyl Diphosphate Synthase or Farnesyltranstransferase or Geranyltranstransferase or GGPS1 or EC 2.5.1.29 or EC 2.5.1.1 or EC 2.5.1.10) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Geranylgeranyl Pyrophosphate Synthase (Geranylgeranyl Diphosphate Synthase or Dimethylallyltranstransferase or Farnesyl Diphosphate Synthase or Farnesyltranstransferase or Geranyltranstransferase or GGPS1 or EC 2.5.1.29 or EC 2.5.1.1 or EC 2.5.1.10) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Geranylgeranyl Pyrophosphate Synthase (Geranylgeranyl Diphosphate Synthase or Dimethylallyltranstransferase or Farnesyl Diphosphate Synthase or Farnesyltranstransferase or Geranyltranstransferase or GGPS1 or EC 2.5.1.29 or EC 2.5.1.1 or EC 2.5.1.10) targeted pipeline therapeutics. The...
-
Product Insights
![]()
Trifunctional Purine Biosynthetic Protein Adenosine 3 (Phosphoribosylglycinamide Formyltransferase or Phosphoribosylamine Glycine Ligase or Phosphoribosylformylglycinamidine Cyclo Ligase or GART or EC 2.1.2.2 or EC 6.3.3.1 or EC 6.3.4.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Trifunctional Purine Biosynthetic Protein Adenosine 3 (Phosphoribosylglycinamide Formyltransferase or Phosphoribosylamine Glycine Ligase or Phosphoribosylformylglycinamidine Cyclo Ligase or GART or EC 2.1.2.2 or EC 6.3.3.1 or EC 6.3.4.13) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Trifunctional Purine Biosynthetic Protein Adenosine 3 (Phosphoribosylglycinamide Formyltransferase or Phosphoribosylamine Glycine Ligase or Phosphoribosylformylglycinamidine Cyclo Ligase or GART or EC 2.1.2.2 or EC 6.3.3.1 or EC 6.3.4.13) targeted pipeline therapeutics. The...
-
Product Insights
![]()
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or EC 3.1.3.16 or EC 3.1.3.48 or EC 3.1.3.67) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Phosphatidylinositol 3,4,5 Trisphosphate 3 Phosphatase And Dual Specificity Protein Phosphatase PTEN (Mutated In Multiple Advanced Cancers 1 or Phosphatase And Tensin Homolog or PTEN or...
-
Product Insights
![]()
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Casein Kinase I Isoform Delta (Tau Protein Kinase CSNK1D or CKI Delta or CSNK1D or EC 2.7.11.1 or EC 2.7.11.26) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of...
-
Product Insights
![]()
Xanthine Dehydrogenase-Oxidase (Xanthine Dehydrogenase or Xanthine Oxidase or Xanthine Oxidoreductase or XDH or EC 1.17.1.4 or EC 1.17.3.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Xanthine Dehydrogenase/Oxidase (Xanthine Dehydrogenase or Xanthine Oxidase or Xanthine Oxidoreductase or XDH or EC 1.17.1.4 or EC 1.17.3.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Xanthine Dehydrogenase/Oxidase (Xanthine Dehydrogenase or Xanthine Oxidase or Xanthine Oxidoreductase or XDH or EC 1.17.1.4 or EC 1.17.3.2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of...
-
Product Insights
![]()
Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The...
-
Product Insights
![]()
Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Angiotensin Converting Enzyme (Dipeptidyl Carboxypeptidase I or Kininase II or CD143 or ACE or EC 3.4.15.1 or EC 3.2.1.) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA),...
-
Product Insights
![]()
Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Farnesyl Pyrophosphate Synthase (Farnesyl Diphosphate Synthase or (2E,6E) Farnesyl Diphosphate Synthase or Dimethylallyltranstransferase or Geranyltranstransferase or FDPS or EC 2.5.1.10 or EC 2.5.1.1) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by...
-
Product Insights
![]()
Prostatic Acid Phosphatase (5 Nucleotidase or Ecto 5 Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Prostatic Acid Phosphatase (5' Nucleotidase or Ecto 5' Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Prostatic Acid Phosphatase (5' Nucleotidase or Ecto 5' Nucleotidase or Thiamine Monophosphatase or ACPP or EC 3.1.3.2 or EC 3.1.3.5) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of...
-
Product Insights
![]()
Protein Kinase C Delta Type (Tyrosine Protein Kinase PRKCD or nPKC Delta or PRKCD or EC 2.7.11.13 or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Protein Kinase C Delta Type (Tyrosine Protein Kinase PRKCD or nPKC Delta or PRKCD or EC 2.7.11.13 or EC 2.7.10.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Protein Kinase C Delta Type (Tyrosine Protein Kinase PRKCD or nPKC Delta or PRKCD or EC 2.7.11.13 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of...
-
Product Insights
![]()
Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Diacylglycerol O Acyltransferase 2 (Diglyceride Acyltransferase 2 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT2 or EC 2.3.1.76 or EC 2.3.1.20) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage...
-
Product Insights
![]()
Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule...
-
Product Insights
![]()
Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Ubiquitin Like Modifier Activating Enzyme 1 (Ubiquitin Activating Enzyme E1 or Protein A1S9 or UBA1 or EC 6.3.2.19 or EC 6.2.1.45) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development,...
-
Product Insights
![]()
Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Bifunctional Epoxide Hydrolase 2 (Cytosolic Epoxide Hydrolase 2 or Epoxide Hydratase or Soluble Epoxide Hydrolase or Lipid Phosphate Phosphatase or EPHX2 or EC 3.3.2.10 or EC 3.1.3.76) targeted pipeline therapeutics. The...
-
Product Insights
![]()
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform (PI3K-Delta or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Delta or PIK3CD or EC 2.7.1.137 or EC 2.7.1.153) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform (PI3K-Delta or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Delta or PIK3CD or EC 2.7.1.137 or EC 2.7.1.153) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform (PI3K-Delta or Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Delta or PIK3CD or EC 2.7.1.137 or EC 2.7.1.153)...
-
Product Insights
![]()
Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or Mediator Complex Subunit CDK8 or CDK8 or EC 2.7.11.22 or EC 2.7.11.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or Mediator Complex Subunit CDK8 or CDK8 or EC 2.7.11.22 or EC 2.7.11.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cyclin Dependent Kinase 8 (Protein Kinase K35 or Mediator Of RNA Polymerase II Transcription Subunit CDK8 or Cell Division Protein Kinase 8 or...
-
Product Insights
![]()
DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox Factor 1 or APEX1 or EC 4.2.99.18 or EC 3.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox Factor 1 or APEX1 or EC 4.2.99.18 or EC 3.1.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on DNA (Apurinic or Apyrimidinic Site) Lyase (APEX Nuclease or APEN or Apurinic Apyrimidinic Endonuclease 1 or AP Endonuclease 1 or REF 1 or Redox...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.